ACR on Air
ACR Convergence 2024: Updated ACR Lupus Nephritis Guideline
Nov 19, 2024
Dr. Lisa R. Sammaritano, a leading expert in lupus at Weill Cornell Medicine, discusses the groundbreaking updates to the ACR Lupus Nephritis Guideline, a decade in the making. She shares insights on innovative treatment strategies, including combination therapies and the push to minimize glucocorticoid use for better patient outcomes. The conversation highlights the unique needs of both pediatric and adult patients, the promise of a triple therapy approach, and challenges in managing class 5 lupus nephritis, emphasizing the importance of individualized care.
33:31
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The 2024 Lupus Nephritis Guidelines highlight a holistic approach and incorporate new FDA-approved therapies, significantly improving patient outcomes.
- The guidelines advocate for a strategic shift towards triple therapy as the first-line treatment, emphasizing reduced glucocorticoid use to minimize toxicity.
Deep dives
Introduction of New Lupus Nephritis Guidelines
The 2024 American College of Rheumatology Lupus Nephritis Guidelines mark a significant update after a decade, incorporating advancements in therapies and a more holistic approach to patient management. The guidelines now reflect new FDA-approved treatments such as bulimumab and voclosporin, which demonstrate improved outcomes for lupus nephritis patients compared to outdated recommendations from 2012. Key outcomes from recent clinical studies have informed this update, underscoring the importance of integrating these innovative therapies into treatment plans. By acknowledging these changes, the new guidelines position healthcare providers to make more informed decisions about lupus nephritis management in clinical practice.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
